Recent News Releases

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category....

CSL Seqirus to provide pandemic influenza vaccine to support 17 EU and EEA countries and the EU Commission in the event of a pandemic declaration. The decision by the Health Emergency Preparedness...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive...

ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the first-in-class...

To date, there have been over 46,300 lab-confirmed influenza cases in Australia, more than 50% higher than the previous record of flu cases in Australia during the first quarter (January – March...